Pharmacoeconomic analysis of different strategies of monotherapy with genetically engineered biological agents in russian patients with rheumatoid arthritis
- Autores: Ryazhenov V.V1, Gorokhova S.G1, Volkova E.R1
-
Afiliações:
- Edição: Nº 7 (2015)
- Páginas: 56-60
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287901
- ID: 287901
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
A comparative pharmacoeconomic analysis of different strategies of monotherapy using genetically engineered biological drugs for adult patients with active rheumatoid arthritis and intolerance or inconvenience of continuation of therapy with disease-modifying antirheumatic drugs was performed. It was revealed that the drug tocilizumab has clinical and economic advantages, which are expressed in terms of a preferable cost-effectiveness.
Texto integral
Bibliografia
- Насонов Е.Л. Сравнительная эффективность генно-инженерных биологических препаратов (ГИБП) при ревматоидном артрите (РА): данные мета-анализов. http:// rheumatolog.ru/files/elnews/compeffbiol.pdf.
- Насонов Е.Л., Каратеев Д.Е. Клинические рекомендации по лечению ревматоидного артрита. http://rheumatolog.ru/files/natrec04. pdf.
- Yazici Y., Shi N., John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull. NYU Hosp. Jt. Dis. 2008;66(2):77-85.
- Soliman M., Ashcroft D.M., Watson K.D., Lunt M., Symmons D.P., Hyrich K.L.; British Society for Rheumatology Biologics Register. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 2011;70:583-9.
- Listing J., Strangfeld A., Rau R., Kekow J., Gromnica-Ihle E., Klopsch T., Demary W., Burmester G.R., Zink A. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis. Res. Ther. 2006;8:R66.
- Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., Cöster L., Geborek P., Jacobsson L.T., Lindblad S., Lysholm J., Rantapаа-Dahlqvist S., Saxne T., van Vollenhoven R.F., Klareskog L. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann. Rheum. Dis. 2007;66:1339-44.
- Gabay C., Emery P., van Vollenhoven R., Dikranian A., Alten R., Pavelka K., Klearman M., Musselman D., Agarwal S., Green J., Kavanaugh A. ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, Turchetti G. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin. Exp. Rheumatol. 2012;30(73):72-84.
Arquivos suplementares
